A Canadian Drug Company Went Public—And the Stock Jumped 17% in Hours. Here's What That Means

What Actually Happened

Apotex Health, a Canadian pharmaceutical company, sold shares to the public for the first time on June 10, 2026. The company priced its shares at C$24 each and raised C$1.3 billion, according to Reuters. This was the top end of the price range the underwriters had announced beforehand.

The deal also got bigger just before pricing. The company and its underwriters—investment banks that handle IPO sales—had originally planned to sell a smaller amount, but demand was so strong they increased the share count. This is a good sign: it means investors wanted in badly enough that the banks felt comfortable upsizing the deal.

The First Day on the Stock Exchange

When shares started trading on the Toronto Stock Exchange, they opened at C$28—about 17% higher than the C$24 IPO price, per Reuters. That gap matters, and it tells two different stories depending on who you ask.

To ordinary investors buying on day one, a 17% jump looks like a win. But to the large institutional investors who got shares directly from the underwriters at C$24, it stings: they see that if they'd waited a few hours, they could have sold at a higher price. Both perspectives are valid. The gap simply reflects that the stock market itself thinks the shares are worth more than the agreed-upon IPO price—which is useful information, but doesn't mean the original pricing was wrong or right.

Why This Deal Is Worth Noting

At C$1.3 billion, this is the largest IPO on the Toronto Stock Exchange in five years. That matters because Canada's stock market has been quiet for a while. Since 2021, fewer big companies have gone public. Interest rates bounced around, growth stocks fell out of favor, and Canadian companies depend heavily on the health of the US economy and commodity prices.

A successful, well-received big deal like this can change the mood. When large institutional investors and underwriters see one major company pull off a clean IPO at strong prices, they call their clients. CEOs who had been waiting to go public but were nervous start thinking the timing is right. If Apotex Health's stock holds up over the next few weeks, you may see other Canadian companies follow.

What the Bigger Deal Tells Us

When underwriters upsize an IPO and the stock still prices at the top of the range, it means the original plan was conservative—which is normal. They build upsizing into every IPO structure as a way to reward their best clients with extra shares if demand is hot. The fact that Apotex could get bigger and still hit the highest price is the real signal: demand wasn't soft at all.

For Apotex, going public at scale is a major turn. The company now has to file quarterly earnings reports, answer to public shareholders, and think carefully about how it spends money and profits. That's a different world from being private.

What to Watch Now

The opening-day pop from C$24 to C$28 is striking, but it only tells you what happened on day one. If the stock stays above C$28 and builds from there, it changes the narrative for other Canadian companies thinking about going public. If it drifts back down over the next two weeks, it sends a different message. The real meaning of this IPO won't be clear for a while.